School of Medicine


Showing 1-10 of 14 Results

  • Anuja Anand Sathe

    Anuja Anand Sathe

    Instructor, Medicine - Oncology

    Current Research and Scholarly InterestsI am interested in understanding the determinants of therapeutic resistance in cancer. I investigate the composition of the tumor microenvironment and adaptive responses to therapy using single-cell RNA sequencing.

  • Lidia Schapira

    Lidia Schapira

    Professor of Medicine (Oncology)

    BioI am a medical oncologist focused on breast cancer and cancer survivorship. My career goal is to improve outcomes and experiences of patients and caregivers living with and beyond cancer, and my research and scholarship have contributed to understanding and meeting the needs of the growing population of cancer survivors. My editorial work for the Journal of Clinical Oncology has given me the opportunity to shape the discourse in oncology and as Editor-in-Chief of Cancer.Net I can bring high quality information about cancer to the lay public.

  • Joseph Schroers-Martin

    Joseph Schroers-Martin

    Instructor, Medicine - Oncology

    Current Research and Scholarly InterestsMedical heme/onc focused on molecular cancer diagnostics and novel biomarkers.

  • Sumit Shah

    Sumit Shah

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Sumit Shah specializes in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. He also serves as an investigator on numerous clinical trials, with a focus on novel immunotherapy agents. His academic interests also include digital health technologies and novel healthcare delivery services, both in the domestic and international setting. Dr. Shah graduated with distinction in biomedical engineering from Duke University, received his medical doctorate from Stanford University, and Masters in Public Health from Harvard University. He completed his internal medicine residency at the University of California, San Francisco (UCSF) where he stayed on faculty for one year before returning to Stanford for his fellowship training in medical oncology, where he now serves on the faculty.

  • Shagufta Shaheen

    Shagufta Shaheen

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Shaheen specializes in the gastrointestinal malignancies and she has expertise in treating neuroendocrine tumors (NETs). Following her fellowship in Hematology and Oncology, Dr Shaheen completed an advanced fellowship in Neuroendocrine tumors from Stanford University. The NET advanced fellowship is first of its kind in United State started under the leadership of Dr Pamela Kunz who is the founding Director of the Stanford Neuroendocrine Tumor Program established in 2015. After completing her advanced fellowship, Dr Shaheen joined Stanford Oncology division as Clinical Assistant Professor. Dr Shaheen is involved in further developing the neuroendocrine oncology program at Stanford which serves as a centre of excellence in the treatment of neuroendocrine tumors. Dr Shaheen is actively involved in clinical research and clinical trials. Dr Shaheen is also involved in taking care of patients admitted to the oncology service as well as resident and fellow teaching.

  • Mohammad Shahrokh Esfahani

    Mohammad Shahrokh Esfahani

    Instructor, Medicine - Oncology

    BioWith a primary focus on high-dimensional data, I have significant expertise in developing machine learning tools. Much of my work involves constructing Bayesian models, which effectively convert 'prior knowledge', either inherent in the dataset or obtained from external sources, into mathematical terms—more specifically, prior probabilities.

    My recent research efforts have centered on the analysis of genetic and epigenetic signals within cell-free DNA assays. This interest in epigenetics led to the development of a pioneering technique known as EPIC-seq, which has broadened our understanding of this complex field.

    It's notable that traditional computational methods in cancer genomics often fall short when confronted with an exceedingly low signal-to-noise ratio—a common scenario in cfDNA analyses. As such, there's an emerging need to devise innovative, robust methods capable of overcoming this limitation—a research area that I'm deeply committed to and actively engaged in.

  • Branimir I. Sikic, M. D.

    Branimir I. Sikic, M. D.

    Professor of Medicine (Oncology), Emeritus

    Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers